GlassScriptPhysician profile
Hoa Nguyen
NPI 1275716920
$14,840.02
in general payments reported to CMS, 2019-2025
26 companies · $1,871 in 2025
The $1,871 reported for 2025 was more than what 93% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,553 · 2020: $2,254 · 2021: $1,571 · 2022: $1,729 · 2023: $2,484 · 2024: $2,378 · 2025: $1,871.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,734.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,733.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $3,919.95 | 2021-2025 | Corevalve Evolut R, Onyx Frontier, Hawkone |
| Medtronic Vascular, INC. | $2,447.43 | 2019-2020 | |
| Edwards Lifesciences Corporation | $1,523.83 | 2019-2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Abbott Laboratories | $757.17 | 2024-2025 | Optis, Pressurewire, Navitor |
| Shockwave Medical, INC | $662.84 | 2020-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Novartis Pharmaceuticals Corporation | $579.44 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $577.98 | 2019-2024 | Xarelto |
| Cordis US Corp. | $575.63 | 2022-2025 | Mynx Control, Precise Pro Rx, S.M.A.R.T. Control |
| Penumbra, INC. | $530.03 | 2021-2025 | Indigo System, Penumbra System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $497.06 | 2019-2025 | Jardiance |
| Amgen INC. | $491.75 | 2019-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $482.71 | 2019-2024 | Farxiga |
| E.R. Squibb & Sons, L.L.C. | $389.17 | 2019-2025 | |
| Pfizer INC. | $245.79 | 2019-2023 | |
| Biotronik INC. | $190.64 | 2019-2020 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $130.21 | 2021-2023 | Verquvo, Bridion |
| Inari Medical, INC. | $129.05 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Cardiva Medical, INC. | $122.37 | 2021 | |
| Abiomed | $121.20 | 2021-2024 | Impella |
| Nuwellis, INC. | $112.88 | 2020 | |
| Philips North America LLC | $93.40 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $81.89 | 2025 | |
| Gilead Sciences, INC. | $78.92 | 2019 | |
| Scpharmaceuticals INC. | $46.18 | 2025 | |
| Boston Scientific Corporation | $33.28 | 2022 | |
| Novo Nordisk INC | $19.22 | 2025 | Ozempic |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hoa Nguyen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.